Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × Flucytosine × CNS × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 9 Astrocytoma 8 Brain Neoplasms 7 Oligodendroglioma 6 Glioma 6 Gliosarcoma 2 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Sarcoma 1 Recurrence 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Melanoma 1 Lymphoma 1 Head and Neck Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Temozolomide 22 Bevacizumab 18 Cyclophosphamide 7 Lomustine 6 Irinotecan 6 Carboplatin 6 3-Iodobenzylguanidine 6 Topotecan 5 Radiotherapy 5 Radiosurgery 4 Nivolumab 4 Filgrastim 4 Everolimus 4 fludarabine phosphate 3 Vincristine 3 Sirolimus 3 IL13-PE38 3 Etoposide 3 Drug Therapy 3 Busulfan 3 Antilymphocyte Serum 3 thymoglobulin 2 sonidegib 2 ribociclib 2 pembrolizumab 2 paclitaxel-Angiopep-2 conjugate 2 olaparib 2 fluorodopa F 18 2 fludarabine 2 etoposide phosphate 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02414165 2020-02-07

Toca5

Tocagen Inc.

Phase 2/3 Terminated

Astrocytoma, Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡